vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar
Company profile
Ticker
VOR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
VOR stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Other Events
5 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Multiple Clinical and Preclinical Presentations at ASH 2023
2 Nov 23
S-8
Registration of securities for employees
30 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Regulation FD Disclosure
9 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
Latest ownership filings
4
Nathan D. Jorgensen
5 Mar 24
4
Tirtha Chakraborty
5 Mar 24
4
ROBERT ANG
5 Mar 24
SC 13D/A
5AM Ventures VI, L.P.
14 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Eyal C. Attar
8 Feb 24
4
ROBERT ANG
8 Feb 24
4
Nathan D. Jorgensen
8 Feb 24
4
Tirtha Chakraborty
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.44 mm | 47.44 mm | 47.44 mm | 47.44 mm | 47.44 mm | 47.44 mm |
Cash burn (monthly) | (no burn) | 1.32 mm | 11.77 mm | 10.22 mm | 9.30 mm | 7.88 mm |
Cash used (since last report) | n/a | 7.87 mm | 70.32 mm | 61.05 mm | 55.55 mm | 47.10 mm |
Cash remaining | n/a | 39.57 mm | -22.88 mm | -13.61 mm | -8.11 mm | 340.85 k |
Runway (months of cash) | n/a | 30.1 | -1.9 | -1.3 | -0.9 | 0.0 |
Institutional ownership, Q3 2023
95.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 2 |
Closed positions | 14 |
Increased positions | 17 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 121.54 bn |
Total shares | 65.05 mm |
Total puts | 3.40 k |
Total calls | 6.20 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 22.75 mm | $48.23 bn |
FMR | 7.65 mm | $16.22 bn |
Paradigm Biocapital Advisors | 6.46 mm | $13.70 bn |
5AM Venture Management | 6.36 mm | $13.49 bn |
5AM Ventures VI | 4.83 mm | $207.76 mm |
Laurion Capital Management | 3.18 mm | $6.75 bn |
Artal | 2.69 mm | $5.70 mm |
BLK Blackrock | 2.11 mm | $4.47 bn |
Vanguard | 1.72 mm | $3.64 bn |
Woodline Partners | 1.11 mm | $2.36 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Nathan D. Jorgensen | Common Stock | Payment of exercise | Dispose F | No | No | 2.27 | 6,310 | 14.32 k | 191,154 |
1 Mar 24 | Tirtha Chakraborty | Common Stock | Payment of exercise | Dispose F | No | No | 2.27 | 5,576 | 12.66 k | 181,093 |
1 Mar 24 | Robert Ang | Common Stock | Payment of exercise | Dispose F | No | No | 2.27 | 12,657 | 28.73 k | 815,480 |
6 Feb 24 | Attar Eyal C. | Common Stock | Payment of exercise | Dispose F | No | No | 2.32 | 1,180 | 2.74 k | 112,853 |
6 Feb 24 | Robert Ang | Common Stock | Payment of exercise | Dispose F | No | No | 2.32 | 2,788 | 6.47 k | 828,137 |
News
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
22 Mar 24
Stifel Maintains Buy on Vor Biopharma, Lowers Price Target to $12
21 Mar 24
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
21 Mar 24
Oppenheimer Reiterates Outperform on Vor Biopharma, Lowers Price Target to $15
21 Mar 24
Vor Biopharma: Q4 Earnings Insights
20 Mar 24
Press releases
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
20 Mar 24
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5 Mar 24
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2 Feb 24
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 Jan 24